A dose block-randomized, double-blind, placebo-controlled, single dose escalating trial to study pharmacokinetics, pharmacodynamics, and tolerability of Ckd-712 after a single intravenous administration in healthy volunteers
Latest Information Update: 10 Feb 2017
At a glance
- Drugs CKD 712 (Primary)
- Indications Sepsis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Chong Kun Dang
- 03 Feb 2017 Results (n=44) assessing changes in cardiac function after administration of CKD-712 published in the Clinical Drug Investigation.
- 20 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics